S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery



Status:Recruiting
Conditions:Colorectal Cancer, Colorectal Cancer, Colorectal Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:9/2/2018
Start Date:October 9, 2017
End Date:June 15, 2023
Contact:Danae Campos
Email:dcampos@swog.org
Phone:2106148808

Use our guide to learn which trials are right for you!

S1613, A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) With HER-2 Amplification

This randomized phase II trial studies how well trastuzumab and pertuzumab work compared to
cetuximab and irinotecan hydrochloride in treating patients with HER2/neu amplified
colorectal cancer that has spread from where it started to other places in the body and
cannot be removed by surgery. Monoclonal antibodies, such as trastuzumab and pertuzumab, may
interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy,
such as cetuximab and irinotecan hydrochloride, work in different ways to stop the growth of
tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them
from spreading. Giving trastuzumab and pertuzumab may work better compared to cetuximab and
irinotecan hydrochloride in treating patients with colorectal cancer.

PRIMARY OBJECTIVES:

I. To evaluate the efficacy of trastuzumab and pertuzumab (TP) (Arm 1) in HER-2 amplified
metastatic colorectal cancer (mCRC) by comparing progression-free survival (PFS) on TP
compared to control arm (Arm 2) of cetuximab and irinotecan hydrochloride (irinotecan)
(CETIRI).

SECONDARY OBJECTIVES:

I. To evaluate the overall response rate (ORR), including confirmed complete and partial
response per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, in treatment Arms 1
and 2.

II. To evaluate the overall survival (OS) in treatment Arms 1 and 2. III. To evaluate the
safety and toxicity of TP compared to CETIRI.

TERTIARY OBJECTIVES:

I. To estimate the rates of PFS, OS, and ORR in patients who crossover to TP (Arm 3) after
disease progression on CETIRI.

II. To bank images for future retrospective analysis. III. To evaluate if HER-2/centromeric
probe (CEP17) signal ratio and HER-2 gene copy number (GCN) are predictive of clinical
efficacy for patients receiving TP versus CETIRI.

IV. To bank tissue and blood samples for other future correlative studies from patients
enrolled on the study.

OUTLINE: Patients with HER2 gene amplification are randomized to 1 of 2 arms.

ARM I: Patients receive pertuzumab intravenously (IV) over 30-60 minutes and trastuzumab IV
over 30-120 minutes on day 1. Courses repeat every 21 days in the absence of disease
progression or unacceptable toxicity.

ARM II: Patients receive cetuximab IV over 60-120 minutes and irinotecan hydrochloride IV
over 90 minutes on day 1. Courses repeat every 14 days in the absence of disease progression
or unacceptable toxicity. Patients with documented disease progression may optionally
crossover to Arm I.

After completion of study treatment, patients are followed up for 3 years.

Inclusion Criteria:

- STEP 1 INITIAL REGISTRATION: HER2 TESTING

- Patients must have histologically or cytologically documented adenocarcinoma of the
colon or rectum that is metastatic or locally advanced and unresectable

- Mutation results:

- All patients must have molecular testing performed in a Clinical Laboratory
Improvement Act (CLIA) certified lab which includes which includes KRAS and NRAS
gene and exon 15 of BRAF gene (BRAF V600E mutation); patients with any known
activating mutation in exon 2 [codons 12 and 13], exon 3 [codons 59 and 61] and
exon 4 [codons 117 and 146]) of KRAS/NRAS genes and in exon 15 (BRAFV600E
mutation) of BRAF gene are not eligible

- Patients must not have been treated with any of the following prior to step 1 initial
registration:

- Cetuximab, panitumumab, or any other monoclonal antibody against EGFR or
inhibitor of EGFR

- HER-2 targeting for treatment of colorectal cancer; patients who have received
prior trastuzumab or pertuzumab for other indications such as prior history of
adjuvant or neoadjuvant breast cancer treatment prior to the development of
advanced colorectal cancer are eligible

- Patients must not have had history of severe toxicity and intolerance to or
hypersensitivity to irinotecan or any other study drug; patients must not have had a
severe infusion-related reaction during any prior therapy with pertuzumab or
trastuzumab

- Patients must have tumor slides available for submission for HER-2 testing; HER-2
testing must be completed by the central lab prior to step 2 randomization

- Patients must be informed of the investigational nature of this study and must sign
and give informed consent in accordance with institutional and federal guidelines; for
step 1 initial registration, the appropriate consent form is the step 1 consent form

- As a part of the OPEN registration process the treating institution's identity is
provided in order to ensure that the current (within 365 days) date of institutional
review board approval for this study has been entered in the system

- STEP 2 RANDOMIZATION

- Patients must have HER-2 amplification as determined by central testing (3+ or 2+ by
immunohistochemistry and HER-2 gene amplification by in situ hybridization with a
ratio of HER-2 gene signals to centromere 17 signals >= 2.0)

- Patients must have measurable disease that is metastatic or locally advanced and
unresectable; imaging used to assess all disease per RECIST 1.1 must have been
completed within 28 days prior to step 2 randomization; all disease must be assessed
and documented on the Baseline Tumor Assessment Form

- Patients must have had at least one prior regimen of systemic chemotherapy for
metastatic or locally advanced, unresectable disease; patients must have progressed
following the most recent therapy; prior treatment with irinotecan is allowed; for
patients that received adjuvant chemotherapy: prior treatment for metastatic disease
is not required for patient who experienced disease recurrence during or within 6
months of completion of adjuvant chemotherapy; if the patient received one line of
adjuvant treatment and had disease recurrence after 6 months of completing
chemotherapy, patients will only be eligible after failing one additional line of
chemotherapy used to treat the metastatic or locally advanced, unresectable disease;
patients who have received >= 3 lines of systemic chemotherapy for metastatic or
locally advanced, unresectable disease are not eligible

- Patients must have completed prior chemotherapy, immunotherapy, or radiation therapy
at least 14 days prior to step 2 randomization and all toxicity must be resolved to
Common Terminology Criteria for Adverse Events (CTCAE) version (v)4.0 grade 1 (with
the exception of CTCAE v4.0 grade 2 neuropathy) prior to step 2 randomization

- Brain metastases are allowed if they have been adequately treated with radiotherapy or
surgery and stable for at least 30 days prior to step 2 randomization; eligible
patients must be neurologically asymptomatic and without corticosteroid treatment for
at least 7 days prior to step 2 randomization

- Patients must have a Zubrod performance status of 0 or 1

- Patients must have a complete physical examination and medical history within 28 days
prior to step 2 randomization

- Absolute neutrophil count (ANC) >= 1,500/mcL

- Platelets >= 75,000/mcL

- Hemoglobin >= 9 g/dL

- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) both =< 5 x
institutional upper limit of normal (IULN)

- Bilirubin =< 1.5 mg/dL

- Calculated creatinine clearance > 30 ml/min within 14 days prior to step 2
randomization

- Patients who have had an echocardiogram performed within 6 months prior to step 2
randomization must have ventricular ejection fraction (left ventricular ejection
fraction [LVEF]) >= 50% or >= within normal limits for the institution

- Patients must not have an uncontrolled intercurrent illness including, but not limited
to diabetes, hypertension, severe infection, severe malnutrition, unstable angina,
class III-IV New York Heart Association (NYHA) congestive heart failure, ventricular
arrhythmias, active ischemic heart disease, or myocardial infarction within 6 months
prior to step 2 randomization

- Patients must not have any known previous or concurrent condition suggesting
susceptibility to hypersensitivity or allergic reactions, including, but not limited
to: known hypersensitivity to any of the study treatments or to excipients of
recombinant human or humanized antibodies; patients with mild or seasonal allergies
may be included after discussion with the study chairs

- Patients must not be planning treatment with other systemic anti-cancer agents (e.g.,
chemotherapy, hormonal therapy, immunotherapy) or other treatments not part of
protocol-specified anti-cancer therapy including concurrent investigational agents of
any type

- No prior malignancy is allowed except for adequately treated basal cell or squamous
cell skin cancer, in situ cervical cancer, ductal carcinoma in situ, other low grade
lesions such as incidental appendix carcinoid, or any other cancer from which the
patient has been disease and treatment free for two years; prostate cancer patients on
active surveillance are eligible

- Patients must not be pregnant or nursing; females of child-bearing potential must have
a negative serum pregnancy test within 7 days prior to registration; women/men of
reproductive potential must have agreed to use an effective contraceptive method while
on study and for at least 7 months after the last dose of study treatment; a woman is
considered to be of "reproductive potential" if she has had menses at any time in the
preceding 12 consecutive months; in addition to routine contraceptive methods,
"effective contraception" also includes heterosexual celibacy and surgery intended to
prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a
hysterectomy, bilateral oophorectomy or bilateral tubal ligation; however, if at any
point a previously celibate patient chooses to become heterosexually active during the
time period for use of contraceptive measures outlined in the protocol, he/she is
responsible for beginning contraceptive measures

- Patients must be given the opportunity to consent to the optional submission of tissue
for future research

- Patients must be informed of the investigational nature of this study and must sign
and give written informed consent in accordance with institutional and federal
guidelines; the appropriate consent form for this registration is the step 2 consent
form

- STEP 2 RANDOMIZATION: As a part of the Oncology Patient Enrollment Network (OPEN)
registration process the treating institution's identity is provided in order to
ensure that the current (within 365 days) date of institutional review board approval
for this study has been entered in the system

- STEP 3 CROSSOVER REGISTRATION (OPTIONAL): Patients must have documented disease
progression while on CETIRI (Arm 2) on this protocol; the Follow-up Tumor Assessment
Form documenting disease progression must be submitted to Southwest Oncology Group
(SWOG) prior to step 3 crossover registration; registration to step 3 crossover must
be within 28 days of discontinuation of CETIRI protocol treatment; patients going off
treatment for any other reason are not eligible

- STEP 3 CROSSOVER REGISTRATION (OPTIONAL): Patients must have a Zubrod performance
status of 0 or 1

- STEP 3 CROSSOVER REGISTRATION (OPTIONAL): ANC >= 1,500/mcL

- STEP 3 CROSSOVER REGISTRATION (OPTIONAL): Platelets >= 75,000/mcL

- STEP 3 CROSSOVER REGISTRATION (OPTIONAL): Hemoglobin >= 9 g/dL

- STEP 3 CROSSOVER REGISTRATION (OPTIONAL): AST and ALT both =< 5 x institutional upper
limit of normal (IULN)

- STEP 3 CROSSOVER REGISTRATION (OPTIONAL): Bilirubin =< 1.5 mg/dL

- STEP 3 CROSSOVER REGISTRATION (OPTIONAL): Calculated creatinine clearance > 30 ml/min
within 14 days prior to step 3 crossover registration

- STEP 3 CROSSOVER REGISTRATION (OPTIONAL): Patients must have left ventricular ejection
fraction (LVEF) >= 50% or >= lower limit of normal for the institution by
echocardiogram within 14 days prior to step 3 crossover registration

- STEP 3 CROSSOVER REGISTRATION (OPTIONAL): Patients must have a magnesium, potassium,
calcium, sodium, bicarbonate, and chloride performed within 14 days prior to step 3
crossover registration

- STEP 3 CROSSOVER REGISTRATION (OPTIONAL): Patients must be informed of the
investigational nature of this study and must sign and give written informed consent
in accordance with institutional and federal guidelines; the appropriate consent form
for this registration is the step 2 consent form

- STEP 3 CROSSOVER REGISTRATION (OPTIONAL): As a part of the OPEN registration process
the treating institution's identity is provided in order to ensure that the current
(within 365 days) date of institutional review board approval for this study has been
entered in the system
We found this trial at
604
sites
Lafayette, Colorado 80026
Principal Investigator: Keren Sturtz
Phone: 303-673-1622
?
mi
from
Lafayette, CO
Click here to add this to my saved trials
1201 Camino de Salud Northeast
Albuquerque, New Mexico 87131
(505) 272-4946
Principal Investigator: Jessica Belmonte
Phone: 505-925-0366
University of New Mexico Cancer Center It’s been 40 years since the New Mexico State...
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
2545 Schoenersville Rd
Bethlehem, Pennsylvania 18017
(484) 884-2200
Principal Investigator: Christopher M. Reynolds
Phone: 734-712-3671
Lehigh Valley Hospital - Muhlenberg At Lehigh Valley Health Network, we continually go the extra...
?
mi
from
Bethlehem, PA
Click here to add this to my saved trials
Bremerton, Washington 98310
Principal Investigator: Mehmet S. Copur
Phone: 308-398-6518
?
mi
from
Bremerton, WA
Click here to add this to my saved trials
1500 E Duarte Rd
Duarte, California 91010
(626) 256-4673
Principal Investigator: Marwan G. Fakih
Phone: 800-826-4673
City of Hope Comprehensive Cancer Center City of Hope is a leading research and treatment...
?
mi
from
Duarte, CA
Click here to add this to my saved trials
1 Hurley Plaza
Flint, Michigan 48503
(810) 262-9000
Principal Investigator: Christopher M. Reynolds
Phone: 734-712-3671
Hurley Medical Center From its founding in 1908, Hurley Medical Center has devoted itself to...
?
mi
from
Flint, MI
Click here to add this to my saved trials
4725 North Federal Highway
Fort Lauderdale, Florida 33308
(954) 771-8000
Principal Investigator: Michael A. Schwartz
Phone: 954-267-7750
Holy Cross Hospital While spirituality plays an essential role in the way that we minister...
?
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
1800 West Charleston Boulevard
Las Vegas, Nevada 89102
(702) 383-2000
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
University Medical Center of Southern Nevada University Medical Center is dedicated to providing the highest...
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
4805 Northeast Glisan Street
Portland, Oregon 97213
(503) 215-1111
Principal Investigator: Gary E. Goodman
Phone: 503-215-2614
Providence Portland Medical Center We strive to give those we serve exceptional, compassionate health care...
?
mi
from
Portland, OR
Click here to add this to my saved trials
Seattle, Washington 98104
Principal Investigator: Gary E. Goodman
Phone: 206-215-3086
?
mi
from
Seattle, WA
Click here to add this to my saved trials
98-1079 Moanalua Road
'Aiea, Hawaii 96701
Principal Investigator: Jared D. Acoba
Phone: 808-486-6000
?
mi
from
'Aiea, HI
Click here to add this to my saved trials
'Aiea, Hawaii 96701
Principal Investigator: Jared D. Acoba
Phone: 808-487-7447
?
mi
from
'Aiea, HI
Click here to add this to my saved trials
2226 Liliha Street
'Aiea, Hawaii 96701
Principal Investigator: Jared D. Acoba
Phone: 808-678-9000
?
mi
from
'Aiea, HI
Click here to add this to my saved trials
Aberdeen, Washington 98520
Principal Investigator: Gary E. Goodman
Phone: 360-412-8958
?
mi
from
Aberdeen, WA
Click here to add this to my saved trials
Adrian, Michigan 49221
Principal Investigator: Rex B. Mowat
Phone: 517-265-0116
?
mi
from
Adrian, MI
Click here to add this to my saved trials
200-298 Avenida Doctor Pedro Albizu Campos
Aguadilla, 00603
Principal Investigator: Luis Baez-Diaz
Phone: 787-997-2222
?
mi
from
Aguadilla,
Click here to add this to my saved trials
1 Akron General Avenue
Akron, Ohio 44307
Principal Investigator: Esther H. Rehmus
Phone: 866-223-8100
?
mi
from
Akron, OH
Click here to add this to my saved trials
Albuquerque, New Mexico 87109
Principal Investigator: Jessica Belmonte
Phone: 505-272-0530
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Albuquerque, New Mexico 87109
Principal Investigator: Jessica Belmonte
Phone: 505-272-0530
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Albuquerque, New Mexico 87102
Principal Investigator: Jessica Belmonte
Phone: 505-272-0530
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Allentown, Pennsylvania 18103
Principal Investigator: Christopher M. Reynolds
Phone: 734-712-3671
?
mi
from
Allentown, PA
Click here to add this to my saved trials
Anaconda, Montana 59711
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
?
mi
from
Anaconda, MT
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Gary E. Goodman
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 98508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
1500 East Medical Center Drive
Ann Arbor, Michigan 48109
800-865-1125
Principal Investigator: Oxana V. Rusher
University of Michigan Comprehensive Cancer Center The U-M Comprehensive Cancer Center's mission is the conquest...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
5301 McAuley Drive
Ann Arbor, Michigan 48197
734-712-3456
Principal Investigator: Christopher M. Reynolds
Phone: 734-712-3671
Saint Joseph Mercy Hospital St. Joseph Mercy Ann Arbor Hospital is a 537-bed teaching hospital...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
921 North Oak Park Boulevard
Arroyo Grande, California 93420
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
?
mi
from
Arroyo Grande, CA
Click here to add this to my saved trials
Asheville, North Carolina 28803
Principal Investigator: Raymond Thertulien
Phone: 828-681-2917
?
mi
from
Asheville, NC
Click here to add this to my saved trials
1625 Maple Lane
Ashland, Wisconsin 54806
Principal Investigator: Bret E. Friday
Phone: 218-786-3308
?
mi
from
Ashland, WI
Click here to add this to my saved trials
1615 Maple Lane
Ashland, Wisconsin 54806
Principal Investigator: Bret E. Friday
?
mi
from
Ashland, WI
Click here to add this to my saved trials
Auburn, California 95602
Principal Investigator: Ari D. Baron
Phone: 415-209-2686
?
mi
from
Auburn, CA
Click here to add this to my saved trials
Auburn, California 95603
Principal Investigator: Ari D. Baron
Phone: 415-209-2686
?
mi
from
Auburn, CA
Click here to add this to my saved trials
Aurora, Colorado 80012
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
?
mi
from
Aurora, CO
Click here to add this to my saved trials
13123 E 16th Ave
Aurora, Colorado 80045
(720) 777-1234
Principal Investigator: Sarah L. Davis
Children's Hospital Colorado At Children's Hospital Colorado, we see more, treat more and heal more...
?
mi
from
Aurora, CO
Click here to add this to my saved trials
12605 East 16th Avenue
Aurora, Colorado 80045
720-848-0000
Principal Investigator: Sarah L. Davis
Phone: 720-848-0650
University of Colorado Hospital, Site Top medical professionals, superior medicine and progressive change make University...
?
mi
from
Aurora, CO
Click here to add this to my saved trials
2000 Ogden Ave
Aurora, Illinois 60504
(630) 978-6200
Principal Investigator: Suparna Mantha
Phone: 630-978-6212
Rush - Copley Medical Center Rush-Copley is proud to be the leading provider of health...
?
mi
from
Aurora, IL
Click here to add this to my saved trials
Aventura, Florida 33180
Principal Investigator: Michael A. Schwartz
Phone: 888-823-5923
?
mi
from
Aventura, FL
Click here to add this to my saved trials
3325 Pocahontas Road
Baker City, Oregon 97814
Principal Investigator: Christopher M. Reynolds
Phone: 734-712-3671
?
mi
from
Baker City, OR
Click here to add this to my saved trials
Ballwin, Missouri 63011
Principal Investigator: Jay W. Carlson
Phone: 314-251-7058
?
mi
from
Ballwin, MO
Click here to add this to my saved trials
22 South Greene Street
Baltimore, Maryland 21201
410-328-7904
Principal Investigator: Yixing Jiang
Phone: 800-888-8823
University of Maryland Greenebaum Cancer Center The University of Maryland Marlene and Stewart Greenebaum Cancer...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
4305 New Shepherdsville Road
Bardstown, Kentucky 40004
Principal Investigator: Mehmet S. Copur
Phone: 308-398-6518
?
mi
from
Bardstown, KY
Click here to add this to my saved trials
Baton Rouge, Louisiana 70809
Principal Investigator: Marc R. Matrana
Phone: 225-761-5346
?
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
Baton Rouge, Louisiana 70816
Principal Investigator: Marc R. Matrana
Phone: 225-761-5346
?
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
Bay City, Michigan 48706
Principal Investigator: Anteneh A. Tesfaye
Phone: 313-576-9790
?
mi
from
Bay City, MI
Click here to add this to my saved trials
3535 Pentagon Boulevard
Beavercreek, Ohio 45431
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
?
mi
from
Beavercreek, OH
Click here to add this to my saved trials
Bellingham, Washington 98225
Principal Investigator: Gary E. Goodman
Phone: 360-715-4133
?
mi
from
Bellingham, WA
Click here to add this to my saved trials
800 Farson Street
Belpre, Ohio 45714
(740) 401-0417
Principal Investigator: Timothy D. Moore
Phone: 800-523-3977
Strecker Cancer Center-Belpre The Memorial Health System's Strecker Cancer Center, Belpre combines the clinical expertise...
?
mi
from
Belpre, OH
Click here to add this to my saved trials
Bend, Oregon 97701
Principal Investigator: Gary E. Goodman
Phone: 541-706-2909
?
mi
from
Bend, OR
Click here to add this to my saved trials
Berkeley, California 94704
Principal Investigator: Ari D. Baron
Phone: 415-209-2686
?
mi
from
Berkeley, CA
Click here to add this to my saved trials
Beverly, Massachusetts 01915
Principal Investigator: Angus P. McIntyre
Phone: 978-922-3000
?
mi
from
Beverly, MA
Click here to add this to my saved trials
Billings, Montana 59101
Principal Investigator: Benjamin T. Marchello
Phone: 800-996-2663
?
mi
from
Billings, MT
Click here to add this to my saved trials
1233 North 30th Street
Billings, Montana 59101
406-237-7000
Principal Investigator: Keren Sturtz
Phone: 406-969-6060
Saint Vincent Healthcare The Sisters of Charity of Leavenworth, Kansas, founded St. Vincent Healthcare in...
?
mi
from
Billings, MT
Click here to add this to my saved trials
Billings, Montana 59102
Principal Investigator: Keren Sturtz
Phone: 800-648-6274
?
mi
from
Billings, MT
Click here to add this to my saved trials
43097 Woodward Avenue
Bloomfield, Michigan 48302
Principal Investigator: Anteneh A. Tesfaye
Phone: 313-576-9790
?
mi
from
Bloomfield, MI
Click here to add this to my saved trials
1505 Eastland Drive
Bloomington, Illinois 61701
309-662-2102
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare-Bloomington Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood diseases. Our...
?
mi
from
Bloomington, IL
Click here to add this to my saved trials
100 E Idaho St
Boise, Idaho 83712
(208) 381-2711
Principal Investigator: Gary E. Goodman
Saint Luke's Mountain States Tumor Institute For more than 100 years, St. Luke
?
mi
from
Boise, ID
Click here to add this to my saved trials
Boise, Idaho 83706
Principal Investigator: Christopher M. Reynolds
Phone: 734-712-3671
?
mi
from
Boise, ID
Click here to add this to my saved trials
Bolivar, Missouri 65613
Principal Investigator: Rakesh Gaur
Phone: 913-948-5588
?
mi
from
Bolivar, MO
Click here to add this to my saved trials
Bonne Terre, Missouri 63628
Principal Investigator: Bryan A. Faller
Phone: 314-996-5569
?
mi
from
Bonne Terre, MO
Click here to add this to my saved trials
1100 Balsam Ave
Boulder, Colorado 80304
(303) 440-2273
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Boulder Community Hospital Founded in 1922 as a community-owned and operated not-for-profit hospital, Boulder Community...
?
mi
from
Boulder, CO
Click here to add this to my saved trials
Boulder, Colorado 80303
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
?
mi
from
Boulder, CO
Click here to add this to my saved trials
915 Highland Blvd
Bozeman, Montana 59715
(406) 414-5000
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
Bozeman Deaconess Hospital Bozeman Deaconess Hospital is a Joint Commission certified, licensed Level III trauma...
?
mi
from
Bozeman, MT
Click here to add this to my saved trials
Brainerd, Minnesota 56401
Principal Investigator: Bret E. Friday
?
mi
from
Brainerd, MN
Click here to add this to my saved trials
Branson, Missouri 65616
Principal Investigator: Jay W. Carlson
Phone: 417-269-4520
?
mi
from
Branson, MO
Click here to add this to my saved trials
Bremerton, Washington 98310
Principal Investigator: Mehmet S. Copur
Phone: 308-398-6518
?
mi
from
Bremerton, WA
Click here to add this to my saved trials
Bridgeport, West Virginia 26330
Principal Investigator: Shalu Pahuja
Phone: 304-293-7374
?
mi
from
Bridgeport, WV
Click here to add this to my saved trials
7575 Grand River Avenue
Brighton, Michigan 48114
Principal Investigator: Christopher M. Reynolds
Phone: 734-712-3671
?
mi
from
Brighton, MI
Click here to add this to my saved trials
7575 Grand River Avenue
Brighton, Michigan 48114
Principal Investigator: Christopher M. Reynolds
Phone: 734-712-3671
?
mi
from
Brighton, MI
Click here to add this to my saved trials
Bryan, Texas 77802
Principal Investigator: Mehmet S. Copur
Phone: 308-398-6518
?
mi
from
Bryan, TX
Click here to add this to my saved trials
130 S Bryn Mawr Ave
Bryn Mawr, Pennsylvania 19010
(484) 337-3000
Principal Investigator: Albert S. DeNittis
Phone: 484-476-2649
Bryn Mawr Hospital Bryn Mawr Hospital, a nationally recognized community teaching hospital, is conveniently located...
?
mi
from
Bryn Mawr, PA
Click here to add this to my saved trials
Burbank, California
Principal Investigator: Gary E. Goodman
Phone: 818-847-4793
?
mi
from
Burbank, CA
Click here to add this to my saved trials
Burien, Washington 98166
Principal Investigator: Mehmet S. Copur
Phone: 308-398-6518
?
mi
from
Burien, WA
Click here to add this to my saved trials
1501 Trousdale Drive
Burlingame, California 94010
Principal Investigator: Ari D. Baron
Phone: 415-209-2686
?
mi
from
Burlingame, CA
Click here to add this to my saved trials
Burlington, Massachusetts 01805
Principal Investigator: Keith E. Stuart
Phone: 781-744-8027
?
mi
from
Burlington, MA
Click here to add this to my saved trials
201 E Nicollet Blvd
Burnsville, Minnesota 55337
(952) 892-2000
Principal Investigator: David M. King
Phone: 952-993-1517
Fairview Ridges Hospital Fairview Ridges Hospital is a 150-bed, Level III Trauma Care facility, offering...
?
mi
from
Burnsville, MN
Click here to add this to my saved trials
3123 Medical Dr
Caldwell, Idaho 83605
Principal Investigator: Christopher M. Reynolds
Phone: 734-712-3671
?
mi
from
Caldwell, ID
Click here to add this to my saved trials
Cameron Park, California 95682
Principal Investigator: Ari D. Baron
Phone: 415-209-2686
?
mi
from
Cameron Park, CA
Click here to add this to my saved trials
210 W Walnut St
Canton, Illinois 61520
309-647-5240
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare - Canton Illinois CancerCare is one of the largest private oncology and hematology...
?
mi
from
Canton, IL
Click here to add this to my saved trials
1600 South Canton Center Road
Canton, Michigan 48188
Principal Investigator: Christopher M. Reynolds
Phone: 734-712-3671
?
mi
from
Canton, MI
Click here to add this to my saved trials
1600 South Canton Center Road
Canton, Michigan 48188
Principal Investigator: Christopher M. Reynolds
Phone: 734-712-3671
?
mi
from
Canton, MI
Click here to add this to my saved trials
211 Saint Francis Drive
Cape Girardeau, Missouri 63703
573-331-3000
Principal Investigator: Bryan A. Faller
Phone: 573-334-2230
Saint Francis Medical Center Saint Francis Medical Center is a 282-bed facility serving more than...
?
mi
from
Cape Girardeau, MO
Click here to add this to my saved trials
789 Mt Auburn Rd
Cape Girardeau, Missouri 63703
(573) 519-4725
Principal Investigator: Bryan A. Faller
Phone: 573-651-5550
Southeast Cancer Center SoutheastHEALTH is a far-reaching network of providers and facilities including Southeast Hospital...
?
mi
from
Cape Girardeau, MO
Click here to add this to my saved trials
Carbondale, Illinois 62902
Principal Investigator: Bryan A. Faller
Phone: 618-457-5200
?
mi
from
Carbondale, IL
Click here to add this to my saved trials
401 North Hooper Street
Caro, Michigan 48723
Principal Investigator: Christopher M. Reynolds
Phone: 734-712-3671
?
mi
from
Caro, MI
Click here to add this to my saved trials
Carson City, Nevada 89703
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
?
mi
from
Carson City, NV
Click here to add this to my saved trials
Carterville, Illinois 62918
Principal Investigator: Bryan A. Faller
Phone: 618-985-3333
?
mi
from
Carterville, IL
Click here to add this to my saved trials
160 S Adams St
Carthage, Illinois 62321
(217) 357-6877
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare - Carthage Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood...
?
mi
from
Carthage, IL
Click here to add this to my saved trials
Castro Valley, California 94546
Principal Investigator: Ari D. Baron
Phone: 510-537-1234
?
mi
from
Castro Valley, CA
Click here to add this to my saved trials
Centerville, Ohio 45459
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
?
mi
from
Centerville, OH
Click here to add this to my saved trials
Centerville, Ohio 45459
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
?
mi
from
Centerville, OH
Click here to add this to my saved trials
Centralia, Illinois 62801
Principal Investigator: Bryan A. Faller
Phone: 217-876-4740
?
mi
from
Centralia, IL
Click here to add this to my saved trials
Centralia, Washington 98531
Principal Investigator: Gary E. Goodman
Phone: 360-412-8958
?
mi
from
Centralia, WA
Click here to add this to my saved trials
Chattanooga, Tennessee 37404
Principal Investigator: Mehmet S. Copur
Phone: 308-398-6518
?
mi
from
Chattanooga, TN
Click here to add this to my saved trials
775 South Main Street
Chelsea, Michigan 48118
Principal Investigator: Christopher M. Reynolds
Phone: 734-712-3671
?
mi
from
Chelsea, MI
Click here to add this to my saved trials
14650 East Old US Highway 12
Chelsea, Michigan 48118
Principal Investigator: Christopher M. Reynolds
Phone: 734-712-3671
?
mi
from
Chelsea, MI
Click here to add this to my saved trials
Cheyenne, Wyoming 82001
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
?
mi
from
Cheyenne, WY
Click here to add this to my saved trials